Innovating Drug Discovery for Pancreatitis
Our Pipeline
Drug Discovery Pipeline for Pancreatitis
Our Pipeline
Pancreatitis Research Support Pipeline
This pipeline is designed for both acuteand chronic pancreatitisstudies, with emphasis on biomarker discovery, immune profiling, and therapeutic target identification.
Innovation Support Pipeline
Pancreatic Cancer Research & Therapeutics
"From Bench to Bedside: Multi-modal Research Acceleration in Pancreatic Oncology"
This pipeline enhances R&D workflows through multi-modal integration, target discovery, and preclinical/clinical transition optimizationfor biotech products aimed at pancreatic cancer.
OUR STORY
Empowering Precision Therapeutics in Cancer Care
We, at GenprotX, based in Oslo, Norway, started our journey with a vision to advance early target discovery for Precision therapeutics in Cancer care. Our innovative platform reduces screen-to-hit time, identifying high-value actionable targets. By targeting proteins involved in Oncogenic pathways, we are continually pushing boundaries in cancer treatment.
Through dedication and cutting-edge technology, GenprotX has evolved into a leading biotechnology company. Our commitment to improving cancer care through early target discovery has propelled us to the forefront of precision therapeutics. We are proud to be at the forefront of innovation, making a tangible difference in the fight against cancer.
WHY WORK WITH US
Transforming Pancreatitis Treatment with Innovative Biotech Solutions
In Vivo-Validated Drug Candidates
Our proprietary drug candidates have demonstrated efficacy in preclinical in vivo modelsof acute and chronic pancreatitis. These results highlight our ability to advance from discovery to disease modification rapidly and reliably.
Expert Team
Our multidisciplinary team of scientists, pharmacologists, and biotech innovators are deeply focused on pancreatic inflammation pathways, combining molecular biology, immunology, and AI-driven screening to uncover novel therapeutic avenues.
Global Reach with Strategic Collaborations
We work with clinical and academic partners globally to fast-track the translation of pancreatitis therapiesfrom lab to clinic. Our integrated pipeline allows us to respond quickly to emerging needs in inflammatory disease research and patient care.
UNIQUE APPROACH
Innovative Biotechnology Solutions
Discover our cutting-edge approach at GenprotX, We are revolutionizing target discovery for Precision therapeutics in Cancer care, advancing early target discovery with our innovative platform.
Our early target discovery platform reduces screen-to-hit time, enabling us to identify high-value actionable targets efficiently. GenprotX's library targets proteins involved in Oncogenic pathways, offering unique solutions for cancer treatment.
OUR TEAM
Meet Our Biotech Team
Ankush Sharma
Cofounder, Early Target Discovery
15+ years experience in Multi-omics target discovery in Solid Tumors / Haematology
Honit piplani
Cofounder, Drug Development
10+ years in drug discovery and development, Clinical trials across fibrotic, inflammatory and oncology indications
Stephen Pandol
Cofounder, Scientific Advisor
30+ years experience in leading and organizing research efforts to develop potential therapies for pancreatic diseases,. He is a noted expert in pancreatic cellular physiology and mechanism of the disease.
Our Pipeline
Our Pipeline
At GenprotX, we are dedicated to pioneering innovative solutions in drug discovery for the pharmaceutical industry. Our drug discovery pipeline showcases cutting-edge methodologies and technologies aimed at developing novel drugs to address unmet medical needs. With a focus on collaboration and scientific excellence, our services at GenprotX are designed to accelerate the process of bringing new therapeutic options to market.
' stroke='rgba(60%2c100%2c198%2c1)' stroke-width='0.527778' stroke-miterlimit='1.5' stroke-linecap='square'/%3e%3cpath d='M13.7291 31.9877L13.6023 31.8147L13.4071 31.9034L9.89045 33.5016L14.0111 17.2167L20.2646 18.9923L16.143 35.2808L13.7291 31.9877Z' fill='rgba(255%2c255%2c255%2c1)' stroke='rgba(60%2c100%2c198%2c1)' stroke-width='0.527778' stroke-miterlimit='1.5' stroke-linecap='square'/%3e%3cpath d='M16.7321 3.01926C17.9475 1.80868 19.8765 1.80868 21.0919 3.01926C21.787 3.71152 22.7534 4.03482 23.7109 3.89538C25.3854 3.65154 26.9459 4.81886 27.2381 6.53378C27.4052 7.51445 28.0025 8.36085 28.8567 8.8275C30.3506 9.64353 30.9467 11.5323 30.204 13.0965C29.7793 13.991 29.7793 15.0372 30.204 15.9317C30.9467 17.4959 30.3506 19.3847 28.8567 20.2007C28.0025 20.6674 27.4052 21.5138 27.2381 22.4944C26.9459 24.2093 25.3854 25.3767 23.7109 25.1328C22.7534 24.9934 21.787 25.3167 21.0919 26.009C19.8765 27.2195 17.9475 27.2195 16.7321 26.009C16.037 25.3167 15.0706 24.9934 14.1131 25.1328C12.4386 25.3767 10.8781 24.2093 10.5859 22.4944C10.4188 21.5138 9.82153 20.6674 8.96727 20.2007C7.47341 19.3847 6.87733 17.4959 7.62001 15.9317C8.04471 15.0372 8.04471 13.991 7.62001 13.0965C6.87733 11.5323 7.47341 9.64353 8.96727 8.8275C9.82153 8.36085 10.4188 7.51445 10.5859 6.53378C10.8781 4.81886 12.4386 3.65154 14.1131 3.89538C15.0706 4.03482 16.037 3.71152 16.7321 3.01926Z' fill='rgba(60%2c100%2c198%2c1)'/%3e%3cpath d='M18.9972 8.97217C18.9972 10.3722 19.5389 11.7151 20.5028 12.7045C21.4667 13.6939 22.9139 14.2499 24.2778 14.2499H24.1389C22.775 14.2499 21.4667 14.806 20.5028 15.7954C19.5389 16.7848 18.9972 18.1277 18.9972 19.5277C18.9972 18.1277 18.4556 16.7848 17.4917 15.7954C16.5278 14.806 15.0861 14.2499 13.7222 14.2499H13.8556C15.2194 14.2499 16.5278 13.6939 17.4917 12.7045C18.4556 11.7151 18.9972 10.3722 18.9972 8.97217Z' fill='rgba(255%2c255%2c255%2c1)'/%3e%3c/svg%3e)
Early Target Discovery for Small Molecules
Small Molecule and Peptides
Specialize in small molecule and peptides research to create groundbreaking solutions for a healthier tomorrow.
